Management of Metastatic Melanoma in 2018

JAMA Oncol. 2018 Jun 1;4(6):857-858. doi: 10.1001/jamaoncol.2018.0170.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents, Immunological / therapeutic use
  • CTLA-4 Antigen / antagonists & inhibitors
  • Disease Management
  • Humans
  • Immunotherapy / methods
  • MAP Kinase Kinase Kinases / analysis
  • MAP Kinase Kinase Kinases / antagonists & inhibitors
  • Melanoma / enzymology
  • Melanoma / secondary*
  • Melanoma / therapy
  • Molecular Targeted Therapy
  • Neoplasm Proteins / analysis
  • Neoplasm Proteins / antagonists & inhibitors
  • Precision Medicine
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins B-raf / analysis
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Immunological
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Neoplasm Proteins
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Protein Kinase Inhibitors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • MAP Kinase Kinase Kinases